CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
NCT04661020 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2026-04-07
Summary
A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Conditions
- Large B-Cell Lymphoma (LBCL)
Interventions
- DRUG
-
CD19 CAR-T cells
Each subject receive CD19 CAR T-cells by intravenous infusion
Sponsors & Collaborators
-
Yake Biotechnology Ltd.
collaborator INDUSTRY -
Zhejiang University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-12-03
- Primary Completion
- 2026-12-20
- Completion
- 2026-12-20
Countries
- China
Study Locations
More Related Trials
-
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
NCT04626908 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
NCT04823091 ·Status: UNKNOWN ·Phase: PHASE1
-
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL
NCT04740203 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
NCT06346912 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.
NCT04697290 ·Status: SUSPENDED ·Phase: EARLY_PHASE1
-
Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
NCT02652910 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma
NCT05585996 ·Status: RECRUITING ·Phase: PHASE1
-
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
NCT05349266 ·Status: UNKNOWN ·Phase: PHASE1
-
CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS
NCT04287309 ·Status: UNKNOWN
-
Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL
NCT05453669 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
NCT04599556 ·Status: RECRUITING ·Phase: PHASE1
-
Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma
NCT05239676 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
NCT06464861 ·Status: RECRUITING ·Phase: PHASE1
-
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
NCT03881761 ·Status: UNKNOWN ·Phase: PHASE1
-
CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation
NCT07117305 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma
NCT04812691 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
NCT04887012 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
NCT05651100 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
NCT04169932 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
NCT04316624 ·Status: COMPLETED ·Phase: PHASE1
-
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
NCT04289220 ·Status: UNKNOWN ·Phase: PHASE1
-
Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL
NCT02656147 ·Status: UNKNOWN ·Phase: PHASE1
-
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
NCT07144020 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
NCT04089215 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
NCT06793241 ·Status: RECRUITING ·Phase: EARLY_PHASE1